For example, CAIX inhibition with SLC-0111 significantly enhanced the efficacy of anti-PD1/anti-CTLA4 immunotherapy in preclinical models of melanoma and triple negative breast cancer [45]. The gene discussed is CA9; the disease is triple-negative breast carcinoma.